Part 6/8:
A key concern addressed by the administration is maintaining innovation within the pharmaceutical sector. Dr. Oz emphasized that the United States' drug prices are artificially high partly because other nations refuse to pay fair prices, leading to less revenue for companies and, consequentially, stifling innovation. By negotiating better prices by leveraging international agreements, the U.S. hopes to ensure that American pharmaceutical companies can sustain their research efforts without compromising the development of new treatments.